In 2017, ATNAHS were proud to have acquired the marketing and distribution rights to Kytril (granisetron) from Roche.
Kytril is indicated for the prevention and treatment of emesis, specifically Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-Induced Nausea and Vomiting (RINV) and Post-Operative Nausea and Vomiting (PONV).1
The Kytril molecule granisetron was developed by chemists working at the British company Beecham around 1988.2
Kytril (granisetron) was licensed in the UK in 1991 by SmithKline Beecham with the commercial rights subsequently transferred to Roche Products.3
Whilst working at Beecham, Wesley Miner and Gareth Sanger discovered that 5-HT3 serotonin receptor antagonists were extremely efficacious pharmacological agents for preventing and treating anti-cancer therapy-induced nausea and vomiting.
Their seminal experimental work translated extremely well to the clinic where Kytril (granisetron) was shown to be highly efficacious in patients.4
Today Kytril (granisetron) continues to be recommended for nausea and vomiting associated with cancer chemotherapy.5
CINV market expected to reach nearly $1.9 billion by the end of 20266
All of the information presented above is factual historical information that is available in the public domain and is included in good faith. It is not the intention to make any new or fresh claims nor to be promotional for the product in question.
For further product information please follow this link to the relevant product page on this site.